Evidence map›Paper›PMID 36943829›Full record

Observational studyPloS one2023

Risk of and duration of protection from SARS-CoV-2 reinfection assessed with real-world data.

Shannon L Reynolds, Harvey W Kaufman, William A Meyer, Chris Bush, Oren Cohen, Kathy Cronin, Carly Kabelac, Sandy Leonard, Steve Anderson, Valentina Petkov and 3 more

Open access · goldFull text readObservational Study
In one paragraph

Observational study in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Shannon L ReynoldsScience and Delivery, Aetion, Inc., New York, New York, United States of America.ORCID 0000-0003-1488-6044
Harvey W KaufmanMedical Affairs, Quest Diagnostics, Secaucus, New Jersey, United States of America.
William A MeyerMedical Affairs, Quest Diagnostics, Secaucus, New Jersey, United States of America.
Chris BushScience and Delivery, Aetion, Inc., New York, New York, United States of America.
Oren CohenOffice of the Chief Medical Office, Labcorp Drug Development, Burlington, North Carolina, United States of America.
Kathy CroninDivision of Cancer Control and Population Science, National Cancer Institute, Bethesda, Maryland, United States of America.
Carly KabelacScience and Delivery, Aetion, Inc., New York, New York, United States of America.ORCID 0000-0002-9870-4027
Sandy LeonardParternships and Real World Data, HealthVerity, Philadelphia, PA, United States of America.ORCID 0000-0002-9876-3596
Steve AndersonOffice of the Chief Medical Office, Labcorp Drug Development, Burlington, North Carolina, United States of America.
Valentina PetkovDivision of Cancer Control and Population Science, National Cancer Institute, Bethesda, Maryland, United States of America.
Douglas LowyDivision of Cancer Control and Population Science, National Cancer Institute, Bethesda, Maryland, United States of America.
Norman SharplessDivision of Cancer Control and Population Science, National Cancer Institute, Bethesda, Maryland, United States of America.
Lynne PenberthyDivision of Cancer Control and Population Science, National Cancer Institute, Bethesda, Maryland, United States of America.
National Cancer Institute · USAetion (United States) · USLabCorp (United States) · USQuest Diagnostics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This retrospective observational study aimed to gain a better understanding of the protective duration of prior SARS-CoV-2 infection against reinfection. The objectives were two-fold: to assess the durability of immunity to SARS-CoV-2 reinfection among initially unvaccinated individuals with previous SARS-CoV-2 infection, and to evaluate the crude SARS-CoV-2 reinfection rate and associated risk factors. During the pandemic era time period from February 29, 2020, through April 30, 2021, 144,678,382 individuals with SARS-CoV-2 molecular diagnostic or antibody test results were studied. Rates of reinfection among index-positive individuals were compared to rates of infection among index-negative individuals. Factors associated with reinfection were evaluated using multivariable logistic regression. For both objectives, the outcome was a subsequent positive molecular diagnostic test result. Consistent with prior findings, the risk of reinfection among index-positive individuals was 87% lower than the risk of infection among index-negative individuals. The duration of protection against reinfection was stable over the median 5 months and up to 1-year follow-up interval. Factors associated with an increased reinfection risk included older age, comorbid immunologic conditions, and living in congregate care settings; healthcare workers had a decreased reinfection risk. This large US population-based study suggests that infection induced immunity is durable for variants circulating pre-Delta predominance.

Indexed as

COVID-19SARS-CoV-2AntibodiesHealth PersonnelHumansReinfectionAntibodies

Identifiers

PMID36943829
PMCPMC10045607
OpenAlexW4328048093

What OpenQuestion holds

Textfull text, public
LicenceCC0
measurements read408
identifiers read8
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.